179 related articles for article (PubMed ID: 22385366)
1. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.
Pfaar O; Jung K; Wolf H; Decot E; Kleine-Tebbe J; Klimek L; Wüstenberg E
Allergy; 2012 May; 67(5):630-7. PubMed ID: 22385366
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio.
Jung K
Allergy; 2011 Jul; 66 Suppl 95():41-3. PubMed ID: 21668852
[TBL] [Abstract][Full Text] [Related]
3. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with an optimized allergen to adjuvant ratio under routine practice conditions: a noninterventional observational study.
Hauswald B; Wolf H; Becker F; Becker S; Schnitker J; Wüstenberg E
J Investig Allergol Clin Immunol; 2013; 23(7):471-7. PubMed ID: 24654311
[TBL] [Abstract][Full Text] [Related]
5. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.
Rask C; Lund L; Lund G; Heydenreich B; Wurtzen P; Bellinghausen I; Saloga J; Lund K
Clin Exp Allergy; 2012 Sep; 42(9):1356-68. PubMed ID: 22925322
[TBL] [Abstract][Full Text] [Related]
6. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
7. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
8. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
Klimek L; Schendzielorz P; Pinol R; Pfaar O
Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
[TBL] [Abstract][Full Text] [Related]
9. Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy.
Tabar AI; González Delgado P; Sánchez Hernández C; Basagaña Torrento M; Moreno Benítez F; Arina M
J Investig Allergol Clin Immunol; 2015; 25(1):40-6. PubMed ID: 25898693
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
11. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
[TBL] [Abstract][Full Text] [Related]
13. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
14. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
15. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
Asero R
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
[TBL] [Abstract][Full Text] [Related]
16. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation.
Pfaar O; van Twuijver E; Hecker H; Boot JD; van Ree R; Klimek L
Int Arch Allergy Immunol; 2013; 160(4):420-4. PubMed ID: 23183541
[TBL] [Abstract][Full Text] [Related]
17. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
19. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
[TBL] [Abstract][Full Text] [Related]
20. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
Kleine-Tebbe J; Ribel M; Herold DA
Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
